Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa.
Indian J Pediatr. 2019 Aug;86(8):717-724. doi: 10.1007/s12098-018-02846-8. Epub 2019 Jan 17.
Approximately 25,000 children develop multidrug-resistant (MDR) tuberculosis (TB) each year, but few of them are diagnosed and appropriately treated for MDR-TB. New diagnostic tools have improved our ability to diagnose children with bacteriologically confirmed TB earlier. However, the majority of childhood TB cases are not bacteriologically confirmed; therefore a high index of suspicion is needed, and taking a detailed history of contact with drug-resistant source cases and previous TB treatment is important to identify presumed MDR-TB cases. Treatment for MDR-TB is rapidly changing with the addition of new and repurposed drugs, the introduction of shorter regimens and the move towards injectable-free, all-oral MDR-TB treatment regimens. Children have been neglected in the introduction of the new drugs, but drug dosing and safety studies are now being completed. This article presents a practical approach in deciding which regimen to use in individual children in need of MDR-TB treatment. Outcomes in those treated are generally good, but only <5% of children with MDR-TB are currently diagnosed and appropriately treated. Diagnosing children with MDR-TB and getting them on to correct treatment regimens should now be our main focus.
每年约有 25000 名儿童罹患耐多药结核病(TB),但其中很少有儿童被诊断出并接受适当的耐多药-TB 治疗。新的诊断工具提高了我们更早诊断出有细菌学确诊结核病的儿童的能力。然而,大多数儿童结核病病例未经细菌学确诊;因此,需要高度怀疑,并详细了解耐药源病例的接触史和以前的结核病治疗情况,以确定疑似耐多药-TB 病例。随着新的和重新利用的药物的加入,较短的方案的引入以及向无注射、全口服耐多药-TB 治疗方案的转变,耐多药-TB 的治疗正在迅速改变。在引入新药时,儿童被忽视了,但现在正在完成药物剂量和安全性研究。本文提出了一种实用的方法,用于决定需要耐多药-TB 治疗的个别儿童使用哪种方案。接受治疗的儿童的结果通常较好,但目前只有<5%的耐多药-TB 儿童被诊断出并接受适当治疗。现在,我们的主要重点应该是诊断耐多药-TB 儿童并让他们接受正确的治疗方案。